Italian Budget Likely To Meet Opposition
The Italian coalition government led by Silvio Berlusconi has approved a budget bill aimed at cutting the state budget deficit by 50,000 billion lire ($31.99 billion), including some 6,300 billion lire ($4.03 billion) reductions in the health sector.
The proposal, which is likely to meet with lively opposition in parliament, calls for some 21,000 billion lire cuts in expenditure and provides for 29,000 billion lire of additional income for the state.
Provisions involving the health sector include a gradual reduction of pharmaceutical prices for those products which have witnessed a strong rise in sales volume after the price liberalization enacted in February, reports the Marketletter's local correspondent.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze